

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently Amended) A method for treating a human with cancer, comprising administering to the human with cancer a composition comprising between approximately  $10^{-2}$  mg to approximately  $10^{-8}$  mg of neuraminidase, wherein the composition does not contain tumor cells.

2. (Previously presented) The method of Claim 1, wherein the composition comprises neuraminidase dissolved in a phenol-saline solution.

Claim 3 cancelled.

4. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered systemically.

5. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.

6. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered sublingually.

7. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered nasally.

8. (Previously presented) The method of Claim 1, wherein cancer is a solid tumor.

9. (Previously presented) The method of Claim 8, wherein cancer is prostrate cancer, pancreatic cancer, melanoma, breast cancer, colon cancer, lymphoma, esophageal cancer, lung cancer, testicular cancer, or brain cancer.

Claims 10, 11 and 12 cancelled.

13. (Previously presented) The method of Claim 1, wherein less than approximately  $10^{-2}$  mg neuraminidase is administered.

14. (Previously presented) The method of Claim 1, wherein approximately  $10^{-3}$  mg to  $10^{-7}$  mg neuraminidase is administered.

15. (Previously presented) The method of Claim 1, wherein approximately  $10^{-4}$  mg neuraminidase is administered.

16. (New) The method of Claim 1, wherein the neuraminidase is administered one to eight times per day.

17. (New) A method for treating a human with cancer, comprising administering to the human a composition consisting essentially of between approximately  $10^{-2}$  mg to approximately  $10^{-8}$  mg of neuraminidase.